David Pendarvis Sells 4,367 Shares of ResMed Inc. (NYSE:RMD) Stock

ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 4,367 shares of the firm’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $147.85, for a total value of $645,660.95. Following the completion of the sale, the insider now owns 128,781 shares of the company’s stock, valued at $19,040,270.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Pendarvis also recently made the following trade(s):

  • On Thursday, October 3rd, David Pendarvis sold 4,367 shares of ResMed stock. The stock was sold at an average price of $128.62, for a total value of $561,683.54.
  • On Tuesday, September 3rd, David Pendarvis sold 4,367 shares of ResMed stock. The stock was sold at an average price of $138.11, for a total value of $603,126.37.

NYSE:RMD opened at $143.25 on Thursday. ResMed Inc. has a twelve month low of $90.64 and a twelve month high of $149.96. The company has a market cap of $21.20 billion, a price-to-earnings ratio of 39.35, a price-to-earnings-growth ratio of 2.82 and a beta of 0.41. The stock has a fifty day simple moving average of $135.58 and a 200-day simple moving average of $125.55. The company has a current ratio of 2.11, a quick ratio of 1.46 and a debt-to-equity ratio of 0.60.

ResMed (NYSE:RMD) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.06. ResMed had a return on equity of 26.72% and a net margin of 15.52%. The business had revenue of $681.06 million during the quarter, compared to the consensus estimate of $660.87 million. During the same period last year, the company earned $0.81 earnings per share. The business’s revenue for the quarter was up 15.8% compared to the same quarter last year. As a group, equities research analysts predict that ResMed Inc. will post 4.04 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Wednesday, November 6th. This represents a $1.56 annualized dividend and a dividend yield of 1.09%. ResMed’s dividend payout ratio (DPR) is 42.86%.

RMD has been the subject of a number of analyst reports. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research report on Friday, October 25th. ValuEngine downgraded ResMed from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Goldman Sachs Group upgraded ResMed from a “neutral” rating to a “buy” rating in a research report on Monday, July 29th. Finally, UBS Group upgraded ResMed from a “neutral” rating to a “buy” rating and raised their price target for the stock from $122.00 to $140.00 in a research report on Monday, July 29th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $121.50.

Several large investors have recently added to or reduced their stakes in RMD. AdvisorNet Financial Inc increased its stake in shares of ResMed by 26.0% during the third quarter. AdvisorNet Financial Inc now owns 392 shares of the medical equipment provider’s stock valued at $53,000 after buying an additional 81 shares during the period. Brasada Capital Management LP increased its stake in shares of ResMed by 1.7% during the third quarter. Brasada Capital Management LP now owns 5,256 shares of the medical equipment provider’s stock valued at $710,000 after buying an additional 87 shares during the period. Altshuler Shaham Ltd increased its stake in shares of ResMed by 6.1% during the second quarter. Altshuler Shaham Ltd now owns 1,539 shares of the medical equipment provider’s stock valued at $642,000 after buying an additional 89 shares during the period. Hartford Investment Management Co. increased its stake in shares of ResMed by 0.6% during the second quarter. Hartford Investment Management Co. now owns 15,894 shares of the medical equipment provider’s stock valued at $1,940,000 after buying an additional 97 shares during the period. Finally, World Asset Management Inc increased its stake in shares of ResMed by 1.0% during the third quarter. World Asset Management Inc now owns 10,117 shares of the medical equipment provider’s stock valued at $1,367,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 66.45% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Featured Article: How is the LIBOR rate calculated?

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.